#heor

[tilliekkosapi]

Curis schach

I had a lot of fun doing these hehe

[mundytheworldfish]

ermmm hello asatmo fandom

[palipil]

edit. тоже не самый новый арт

откуда перс: видео на ютуб "K1LLЕD BY ANGEL" на канале Alice Schach and the Magic Orchestra

[negativespace06]

a bunch of unfinished drawings/doodles

[chiruyuki]

I made singable lyrics for KILLED BY ANGEL! Original song and translated lyrics by @alice-orchestra!

P.S. It may take a couple tries to perfect the speed of certain lines, as their rhythm's deliberately distorted! Lyrics are in EN only!

Now, spit out all of your fears

Let us mix and merge and turn into one

Nutrients, vitamins, and minerals

To every starving cell

"I'm done with your fantasies"

Why, I'm telling the truth

Yet, the strange theology tries to silence me

With a rusty red guillotine

"Your whole existence is a nuisance"

As you wished, I should not have been born into this cruel, cruel world

You spew all your desires into the womb and when you no longer need it,

It's all off to the trash bags

What a pretty fate!

That's right, it's all because of this nuisance of a brain

This is the culprit of all of our suffering

Stop working please!

End my suffering!

My poor little chick, lost and hurt

Suddenly, thrown into the darkness

Bury such a disgusting, hideous caricature

Follow the guidance of hea--

"A wretched soul not even God will save"

Crystalline euphoria, let me soar beyond the bright bright bright rainbow

Liars, bullies, and thieves are shamed with a high voice; my high high high holy voice

You will never be able to touch the reborn me!

[graphicabhi]

📊Top HEOR Analysis Firms Powering Better Healthcare Decisions

HEOR analysis firms play a key role in proving treatment value and strengthening market access strategies. DelveInsight provides HEOR services that generate real-world evidence, cost-effectiveness insights, and outcomes research to support data-driven healthcare innovation.

👉 Explore HEOR solutions for smarter healthcare decisions: https://www.delveinsight.com/heor-analysis?utm_source=heor&utm_medium=toparticle&utm_campaign=akpr

[graphicabhi]

Unlocking the True Value of Therapies Through Health Economics Research

The global healthcare conversation has fundamentally changed. Where clinical efficacy once stood alone as the primary measure of a therapy's worth, today's payers, regulators, and integrated delivery networks demand a far richer evidence base. Health economics and outcomes research has risen to meet this demand, equipping stakeholders with the frameworks needed to assess treatments across clinical, economic, and humanistic dimensions simultaneously.

At the heart of this shift lies value based healthcare analysis. This analytical lens reframes the central question of healthcare from "what does this treatment cost?" to "what does this treatment deliver per dollar spent?" Health systems embracing value-based principles are redesigning care pathways, renegotiating supplier contracts, and building population health programs rooted in outcome measurement. For pharmaceutical and medical technology companies, demonstrating value in these terms has become a prerequisite for market relevance, not merely a differentiator.

Understanding how therapies perform across large, diverse populations requires tools that extend beyond the clinical trial environment. Real world data analysis healthcare addresses this need by drawing on observational data from electronic health records, pharmacy claims, patient-reported outcomes, and disease registries. These data sources capture the lived experience of patients in routine care settings — including subgroups often excluded from pivotal trials, such as elderly patients, those with comorbidities, and individuals from underrepresented communities. Insights derived from this data are increasingly shaping regulatory submissions, label expansions, and post-market surveillance strategies.

Effective health economics work also demands careful attention to healthcare cost analysis methods. Whether analysts employ cost-minimization, cost-effectiveness, or cost-utility frameworks, the rigor and consistency of their methodological choices determine the credibility of their findings. Increasingly, health technology assessment agencies publish detailed guidance on preferred analytic approaches, discount rates, time horizons, and sensitivity analysis requirements. Navigating this methodological complexity demands deep expertise and a thorough understanding of each agency's specific evidentiary standards.

Beyond individual therapy assessments, economic burden analysis healthcare provides the broader societal context within which those therapies operate. By quantifying the full cost of diseases — including direct medical expenditures, productivity losses, and informal caregiving costs — these studies establish the baseline against which new interventions are evaluated. They also serve as powerful advocacy tools, helping patient organizations and public health bodies make the case for increased research funding, prevention programs, and expanded access to existing treatments.

The pathway from evidence generation to market access hinges substantially on pricing and market access analysis. Manufacturers must anticipate how payers and health technology assessment bodies will evaluate their products, often beginning market access planning during early clinical development. Price negotiations, reference pricing mechanisms, managed entry agreements, and formulary tiering decisions all depend on the quality and relevance of the economic evidence submitted. Companies that fail to build a compelling access narrative early risk commercial underperformance even when their science is sound.

Perhaps the most integrative of these disciplines is clinical and economic outcomes analysis. By synthesizing data from clinical trials, observational studies, and administrative databases, this approach generates the composite picture that modern decision-makers require. It answers not just whether a treatment works, but for whom it works best, at what cost, and under which clinical conditions — the questions that ultimately determine whether a therapy finds its rightful place in the standard of care.

The sophistication of modern health economic analysis reflects the complexity of the problems it must solve. As drug development costs rise and the global burden of chronic and rare disease expands, the pressure to demonstrate value rigorously and transparently will only grow stronger.

Conclusion

Health economics research has evolved from a niche academic discipline into a strategic imperative for every stakeholder in the healthcare value chain. By combining real-world evidence, cost analysis, and outcomes measurement, these frameworks create the shared language that connects innovation to access. Organizations mastering this evidence ecosystem will shape the future of sustainable, patient-centered healthcare delivery worldwide.

[madeai]

2026 Prediction #4: Agentic AI is Revolutionizing the Next Phase of Continuous Evidence Generation in Pharma

For years, the pharmaceutical industry has followed a familiar cycle: design a clinical trial, execute it, lock the database, analyze the results, and then wait for the next study to answer remaining questions. Wait for post-market surveillance to show real-world outcomes. Wait for regulators or payers to request more data before approving reimbursement. However, this long-standing rhythm is beginning to change in 2026.

Questions multiply faster than discrete studies can answer them. Precision medicine requires evidence for specific patient groups. Health technology assessment bodies seek comparative effectiveness across pathways. Regulators require continuous safety monitoring throughout a product’s life. Patients want to know if a therapy suits someone like them, not just an average from years-old trials. Therefore, our fourth prediction stands clear: by the end of 2026, how we generate evidence in pharmaceutical development will change from isolated events to continuous evidence generation. This means agent-led processes are integrated into clinical research and routine care.

The Growing Evidence Gap in Traditional Approaches

Traditional clinical trials deliver high-quality evidence, yet they remain limited. A Phase III trial enrolls selected patients, measures predefined endpoints, and captures a snapshot of efficacy and safety. This informs approval, but stakeholders need much more.

Providers ask how therapies perform in comorbid patients excluded from trials. Payers seek comparative data against alternatives for coverage. HTA bodies require real-world cost-effectiveness proof. Precision medicine further fragments needs. Different biomarkers, genetics, or stages each require validation.

Statistics highlight the inefficiency. Only about 20% of leading companies create integrated lifecycle evidence plans. Trials often need amendments (76% of Phase I-IV studies), adding months and high costs. We generate evidence too slowly, for too narrow groups, and miss many real-world questions.

How Agentic AI Enables Continuous Evidence Generation

Agentic AI shifts evidence development from reactive to proactive. Unlike earlier tools that automated single tasks, these systems perceive context, reason through scenarios, plan workflows, and act toward goals with limited human input.

In evidence contexts, agents continuously monitor real-world streams, spot emerging gaps, design studies to address them, orchestrate multi-source data collection, synthesize insights, and deliver tailored findings. Often, they anticipate stakeholder needs.

Three capabilities set 2026 systems apart:

Autonomous study design and optimization: Agents review literature, analyze competitors, assess site feasibility, and propose optimized protocols based on real-world likelihood of success.

Continuous real-world evidence synthesis: Agents watch EHRs, claims, registries, and wearables in real time, flagging patterns like safety signals or new efficacy subgroups to trigger deeper analysis.

Adaptive evidence delivery: Living repositories generate on-demand, audience-specific analytics, updating models and scenarios instantly for HTA requests or payer queries.

From Episodes to Ecosystems: The Architecture Shift in Continuous Evidence Generation

Traditional evidence follows isolated episodes: plan, execute, analyze, publish, archive. Each study stands alone.

Continuous evidence generation demands a living ecosystem architecture. Organizations in 2026 converge on key patterns.

Traditional vs. Continuous Evidence Generation

Real-World Implementations in 2026

The shift from theoretical possibility to operational reality is happening now. Multiple pharmaceutical organizations and technology providers launched production systems in early 2026 that demonstrate what continuous evidence generation looks like in practice.

MadeAi’s AI-Powered Evidence Synthesis Platform

MadeAi-LR streamlines the evidence synthesis for HEOR, Medical Affairs, Market Access, and RWE in life sciences. It enables teams to scale operations, reduces timelines, and delivers high-quality services across the full evidence synthesis lifecycle, from protocol development and smart literature search through AI-assisted screening, data extraction, summarization, and final report authoring.

Recursion’s ClinTech Initiative

AI-driven drug developer Recursion has deployed agentic systems focused on three pillars: smarter trial design, accelerated enrollment, and enhanced evidence generation. Their agents continuously analyze internal compound libraries, published literature, competitive trial data, and real-world patient populations to identify optimal study parameters before human teams finalize protocols. The system has reduced protocol amendment rates by identifying mismatches between design assumptions and operational realities before trials launch.

ConcertAI’s Accelerated Clinical Trials Platform

Launched at SCOPE 2026, specialized agents handle literature scanning, protocol design, feasibility, and real-time patient matching from EHRs. Reports show up to 50% reductions in design timelines and amendments.

IQVIA’s Agentic Trial Workflows

IQVIA’s implementation focuses on the operational bottlenecks that plague trial execution, including site activation, startup activities, and data review setup. Agents automate administrative gaps in site activation, startup, and data review, freeing teams for safety and quality focus.

Bridging Clinical Research and Routine Care

Agentic systems help research-embedded care to become a practical reality. Trials integrate into EHRs, workflows, and ordering processes, reducing burden and generating immediately applicable evidence from real patterns.

Recent publications by the FDA’s Real-World Evidence Framework and ICH E6(R3) Good Clinical Practice Guideline emphasize unified ecosystems with methodological safeguards for routine-care evidence.

The infrastructure requirements extend beyond the technical aspects. Health systems must value trials in care, payments support longitudinal collection, and IRBs streamline pragmatic designs. Culture change matters as much as technical capability.

Trust, Transparency, and the Human Element

Autonomous evidence generation raises fundamental questions about trust and oversight. When AI agents design studies, recruit patients, monitor safety signals, and synthesize findings with minimal human intervention, how do we ensure scientific rigor? How do we maintain accountability? How do we prevent automation from introducing systematic biases that human reviewers might catch?

The principle emerging as best practice: automation should augment human expertise, not replace it. The most effective systems combine both, with clear delineation of where the machine stops and the human begins.

Data quality remains paramount, and agentic systems are only as good as the data they consume. Incomplete electronic health records, inconsistent coding practices, fragmented data across systems, and biased datasets all propagate into agent-generated evidence. Organizations investing in continuous evidence generation must invest equally in data infrastructure, standardization, and governance.

Measuring Impact: Early Adopter Results

Early adopters of agent-led evidence generation are reporting measurable improvements across multiple dimensions:

Timeline Compression: Study design timelines reduced 25–50%

Cost Reduction: Protocol amendments down ~50%, saving costs and time

Enrollment Acceleration: Recruitment accelerated 25–50% with better diversity

Evidence Spread: Broader evidence answering multiple questions from unified data

Operational Efficiency: CRAs redirect 30–40% time from admin to oversight

Clinical outcomes matter most: better decisions, precise matching, faster signal detection.

The Regulatory and Reimbursement Landscape

Regulators are moving forward carefully. The FDA supports the use of real-world evidence, while the EMA and MHRA are building clear guidelines. Transparency is essential, and teams need to show how AI works, what data it uses, and its limits. Living documentation helps keep compliance up to date in real time.

HTA bodies face format challenges but gain from dynamic analytics. Collaboration refines requirements.

The Future: The 2027 Evidence Landscape

By late 2027, continuous evidence generation will become standard for leaders. Advantages include faster access, stronger payer ties, improved outcomes, and lower costs.

Technology matures: better reasoning, uncertainty handling, multi-stakeholder optimization. Data interoperability advances. Regulations clarify AI evidence expectations.

Cultural shifts redefine roles. Experts curate graphs, monitor agents, interpret insights, and guide strategy. Work focuses on the right questions and wise application.

The Evidence Revolution

We’re witnessing the transformation of evidence generation from a bottleneck in pharmaceutical development to a continuous flow that keeps pace with the questions we need to answer. Agentic AI makes this possible by automating the orchestration of complex, multi-source data synthesis while maintaining the rigor that regulatory decisions and patient safety demand.

Leaders integrate generation into research and care, build trust via transparency, and use insights for faster decisions. In 2026, evidence becomes continuous, adaptive, comprehensive, and integrated, not consulted retrospectively. The pharmaceutical industry has needed this transformation for decades. The technology, the regulatory environment, and the competitive pressures have finally aligned to make it possible.

Key Takeaways

Traditional trials provide snapshots, missing many stakeholder questions.

Agentic AI enables autonomous design, real-world synthesis, and tailored delivery in real time.

2026 implementations cut timelines and amendments by 25–50%.

Research-care integration yields real-world, diverse evidence.

Success demands guardrails: oversight, audits, and quality validation.

Author’s Note: This article was supported by AI-based research and writing, with Claude 4.5 assisting in the creation of text and images.